Evidence map›Paper›PMID 42581109›Full record

ArticleAnalytical and bioanalytical chemistry2026

N-Terminal protein sequencing by nicotinic acid derivatization and MS analysis.

Peter Gehrig, Simone Wüthrich, Serge Chesnov, Ralph Schlapbach, Paolo Nanni

Abstract read
In one paragraph

Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Peter GehrigFunctional Genomics Center Zurich, University of Zurich/ETH Zurich, Zurich, Switzerland. peter.gehrig@fgcz.uzh.ch.ORCID http://orcid.org/0000-0002-6006-4271
Simone WüthrichFunctional Genomics Center Zurich, University of Zurich/ETH Zurich, Zurich, Switzerland.
Serge ChesnovFunctional Genomics Center Zurich, University of Zurich/ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0003-4037-6283
Ralph SchlapbachFunctional Genomics Center Zurich, University of Zurich/ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0002-7488-4262
Paolo NanniFunctional Genomics Center Zurich, University of Zurich/ETH Zurich, Zurich, Switzerland.ORCID http://orcid.org/0000-0001-8429-3557

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most MS-based workflows for N-terminal protein sequence analysis rely on the modification of primary amines at the protein N-terminus and lysine residues, in many cases through dimethylation. However, incomplete dimethyl labeling and undesired side reactions have been reported previously and were also observed in our experiments. In this study, we evaluated alternative methods for N-terminal protein derivatization. For reductive dimethylation, the highly toxic reducing agent sodium cyanoborohydride was successfully replaced by pyridine borane. In addition, several single-reagent labeling methods were applied to model proteins and compared to the dimethylation workflow. Criteria for the selection of suitable reagents were completeness and selectivity of the protein derivatization reaction, the detection sensitivity for modified peptides by mass spectrometry, and the absence of undesirable side reactions. Comparative analyses demonstrated that the chemical derivatization of free amines by nicotinic acid N-hydroxysuccinimide ester is a particularly promising approach for N-terminal protein sequencing. Protocols for the nicotinoylation of proteins in solution or in gel using this reagent were optimized and successfully applied to various test proteins.

Indexed as

Mass SpectrometryNiacinProteinsSequence Analysis, ProteinAmino Acid SequenceMethylationNiacinProteinsDimethylationNicotinic acidN-TerminalN-TerminomicsProtein sequencing

Identifiers

PMID42581109
PMCPMC13658373

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.